, Volume 172, Issue 2, pp 233–240 | Cite as

Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli

  • J. C. WinterEmail author
  • J. R. Eckler
  • R. A. Rabin
Original Investigation



On the basis of electrophysiological evidence, it has been proposed that both antagonism of NMDA receptors by drugs such as PCP and stimulation of 5- HT2A receptors by drugs such as LSD result in the release of glutamate. Furthermore, it has been observed that antagonists and agonists at mGlu2/3 receptors increase and decrease, respectively, the release of glutamate. Taken together, these observations predict behaviorally significant interactions between ligands at mGlu2/3 receptors and hallucinogens such as LSD and PCP.


The present study sought to test in rats the glutamate hypothesis of hallucinogenesis using drug-induced stimulus control as the dependent variable and selected glutamatergic and serotonergic receptor ligands as independent variables.


Male F-344 rats were trained in a two-lever, fixed ratio 10, food-reinforced task with either phencyclidine (PCP; 3.0 mg/kg; IP; 30 min pretreatment) or lysergic acid diethylamide (LSD; 0.1 mg/kg; IP; 15 min pretreatment) as discriminative stimuli. The interactions of PCP and the mGlu2/3 selective ligands, LY341495 and LY379268, with stimulus control by LSD were determined. The effects of these drugs were compared with those of serotonergic antagonists known to antagonize the stimulus effects of LSD, specifically, pirenperone and M100907.


Stimulus control by LSD was potentiated by both PCP and the mGlu2/3 antagonist, LY341495. In tests of antagonism, stimulus control by LSD was significantly but incompletely diminished by the mGlu2/3 agonist, LY379268; this result was in contrast with the complete antagonism of LSD by both pirenperone and M100907. In PCP-trained rats, LY341495 was without effect on stimulus control by an intermediate dose of PCP. In contrast, the training dose of PCP was significantly but incompletely antagonized by LY379268.


These data, obtained using a stimulus control model of the hallucinogenic effects of PCP and LSD, provide support for the hypothesis that glutamate release is a factor in hallucinogenesis by both 5-HT2 agonists and non-competitive NMDA antagonists.


Lysergic acid diethylamide (LSD) Phencyclidine (PCP) Drug discrimination Rat LY341495 LY379268 



This study was supported in part by National Service Research Award F30 DA14238 (J.R.E.) and by US Public Health Service Grant DA 03385 (R.A.R., J.C.W.).


  1. Adams B, Moghaddam B (2001) Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 50:750–757CrossRefPubMedGoogle Scholar
  2. Aghajanian GK, Marek GJ (1999a) Serotonin and hallucinogens. Neuropsychopharmacology 21:16S–23SCrossRefPubMedGoogle Scholar
  3. Aghajanian GK, Marek GJ (1999b) Serotonin-glutamate interactions: new target for antipsychotic drugs. Neuropsychopharmacology 21:S122–S133Google Scholar
  4. Aghajanian GK, Marek GJ (2000) Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Rev 31:302–312PubMedGoogle Scholar
  5. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol 79:565–575PubMedGoogle Scholar
  6. Ator NA (1990) Drug discrimination and drug stimulus generalization with anxiolytics. Drug Dev Res 20:189–204Google Scholar
  7. Balster RL (1990) Perception of drug effects. In: Berkeley MA, Stebbens WG (eds) Comparative perception (vol 1). Wiley, New York, pp 127–154Google Scholar
  8. Balster RL, Willetts J (1996) Phencyclidine: a drug of abuse and a tool for neuroscience research. In: Shuster CR, Kuhar MJ (eds) Pharmacological aspects of drug dependence: towards an integrated neurobehavioral approach. Springer, Berlin, pp 233–262Google Scholar
  9. Brauer LH, Goudie AJ, deWit H (1997) Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology 130:2–13CrossRefPubMedGoogle Scholar
  10. Breese, GR, Knapp, DJ, Moy, SS (2002) Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness. Neurosci Biobehav Rev 26:441–455CrossRefPubMedGoogle Scholar
  11. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237–260CrossRefPubMedGoogle Scholar
  12. Cartmell J, Schoepp DD (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:899–907Google Scholar
  13. Cartmell J, Monn JA, Schoepp DD (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and Ly379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther 291:161–170PubMedGoogle Scholar
  14. Cartmell J, Monn JA, Schoepp DD (2000) Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268, and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 148:423–429CrossRefPubMedGoogle Scholar
  15. Compton AD, Slemmer JE, Drew MR, Hyman JM, Golden KM, Balster RL, Wiley JL (2001) Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats. Neuropharmacology 40:289–297CrossRefPubMedGoogle Scholar
  16. Conn PJ, Pin J-P (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205–237PubMedGoogle Scholar
  17. Corbett R, Zhou L, Sorensen SM, Mondadori C (1999) Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharmacology 21:S211–S218CrossRefGoogle Scholar
  18. Dall’Olio R, Gaggi R, Bonfante V, Gandolfi O (1999) The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol 10:63–71PubMedGoogle Scholar
  19. Fiorella D, Helsley SE, Rabin RA, Winter JC (1995a) The interactions of typical and atypical antipsychotics with the (−)-DOM discriminative stimulus. Neuropharmacology 34:1297–1303CrossRefPubMedGoogle Scholar
  20. Fiorella D, Palumbo PA, Rabin RA, Winter JC (1995b) The time-dependent stimulus effects of R(−)-2,5-dimethoxy-4-methamphetamine ((−)-DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents. Psychopharmacology 119:239–245PubMedGoogle Scholar
  21. Fiorella D, Rabin RA, Winter JC (1995c) The role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis. Psychopharmacology 121:347–356Google Scholar
  22. Gewirtz JC, Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23:569–576CrossRefPubMedGoogle Scholar
  23. Habara T, Hamamura T, Miki M, Ohashi K, Kuroda S (2001) M100907, a selective 5-HT2A receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain. Eur J Pharmacol 417:189–194CrossRefPubMedGoogle Scholar
  24. Heffter A (1897) Uber Pellote. Arch Exptl Pathol Pharmakol 40:418–425Google Scholar
  25. Hirschhorn ID, Winter JC (1971) Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli. Psychopharmacology 22:64–71Google Scholar
  26. Hofmann A (1959) Psychotomimetic drugs, chemical and pharmacological aspects. Acta Physiol Pharmacol Neerl 8:240–258PubMedGoogle Scholar
  27. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308PubMedGoogle Scholar
  28. Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia. Mol Pharmacol 7:837–844CrossRefGoogle Scholar
  29. Keenan KP, Smith PF, Hertzog P, Soper K, Ballam GC, Clark RL (1994) The effects of overfeeding and dietary restriction on Sprague-Dawley rat survival and early pathology biomarkers of aging. Toxicol Pathol 22:300–315PubMedGoogle Scholar
  30. Kim HS, Park IS, Park WK (1998) NMDA receptor antagonists enhance 5-HT2 receptor mediated behavior, head twitch response, in mice. Life Sci 63:2305–2311CrossRefPubMedGoogle Scholar
  31. Kim HS, Park IS, Lim, HK (1999) NMDA receptor antagonists enhance 5-HT2 receptor mediated behavior, head twitch response, in PCPA-treated mice. Arch Pharm Res 22:113–118PubMedGoogle Scholar
  32. Klodzinska A, Bijak M, Tokarski K, Pilc A (2002) Group II mGlu receptor agonists inhibit behavioral and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 73:327–332CrossRefPubMedGoogle Scholar
  33. Koek W (1999) N-Methyl-d-aspartate antagonists and drug discrimination. Pharmacol Biochem Behav 64:275–281CrossRefPubMedGoogle Scholar
  34. Krystal JH, Belger A, D’Souza DC, Anand A, Charney DS, Aghajanian GK, Moghaddam B (1999) Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 22:S143–S157CrossRefGoogle Scholar
  35. Luby ED (1981) Phencyclidine revisited. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 25–30Google Scholar
  36. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R (1959) Study of the new schizophrenomimetic drug l-sernyl. Arch Neurol Psychiatry 81:363–368Google Scholar
  37. Mansbach RS, Balster RL (1991) Pharmacological specificity of the phencyclidine discriminative stimulus in rats. Pharmacol Biochem Behav 39:971–975CrossRefPubMedGoogle Scholar
  38. Marek GJ (2000) A novel approach to the identification of psychiatric drugs: serotonin-glutamate interactions in the prefrontal cortex. CNS Drug Rev 6:206–218Google Scholar
  39. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76–87Google Scholar
  40. Martin-Ruiz R, Puig MV, Celada P, Shapiron DA, Roth BL, Mengod G, Artigas F (2001) Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors thorough a glutamate-dependent mechanism. J Neurosci 21:9856–9866PubMedGoogle Scholar
  41. Maurel-Remy S, Bervoets K, Millan MJ (1995) Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors. Eur J Pharmacol 280:R9–R11PubMedGoogle Scholar
  42. Meert T, Stolerman I (1999) Drug discrimination in behavioral neuroscience. Pharmacol Biochem Behav 64:191–453CrossRefGoogle Scholar
  43. Miner LAH, Backstrom JR, Sanders-Bush E, Sesack SR (2003) Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 116:107–117CrossRefPubMedGoogle Scholar
  44. Moghaddam B, Adams BW (1998) Reversal of phencylidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349–1352PubMedGoogle Scholar
  45. Nabeshima T, Ishikawa K, Yamiguchi K, Furakawa H, Kameyama T (1984a) Phencyclidine interacts with serotonin2 but not serotonin1 receptor. Res Commun Subst Abuse 5:81–87Google Scholar
  46. Nabeshima T, Noda Y, Ishikawa K, Furakawa, Kameyama T (1984b) Phencyclidine decreases binding capacity of serotonin2 receptor in vitro. Res Commun Subst Abuse 5:175–186Google Scholar
  47. Nabeshima T, Ishikawa K, Yamiguchi K, Furakawa H, Kameyama T (1988) Protection with phencyclidine against inactivation of 5-HT2 receptors by sulfhydral-modifying reagents. Biochem Pharmacol 37:3277–3283CrossRefPubMedGoogle Scholar
  48. Olney JW, Farber NB (1995) NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology 13:335–345CrossRefPubMedGoogle Scholar
  49. Ossowska K, Pietraszek M, Warda J, Zajaczkowski W, Wolfarth S, Pilc A (2000) The role of glutamate receptors in antipsychotic drug action. Amino Acids 19:87–94PubMedGoogle Scholar
  50. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994) Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for functional significance of receptor subtypes. Neurosci Biobehav Rev 18:355–372PubMedGoogle Scholar
  51. Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 299:12–20Google Scholar
  52. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) DOI-induced head-twitches in the rat are mediated by 5-HT2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists, and 5-HT1A agonists. J Pharmacol Exp Ther 273:101–112PubMedGoogle Scholar
  53. Schreiber R, Lowe D, Voerste A, De Vry J (2000) LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 388:R3–R4PubMedGoogle Scholar
  54. Schuster C, Johanson C (1988) Relationship between the discriminative stimulus properties and subjective effects of drugs In: Colpaert F, Balster R (eds) Transduction mechanisms of drug stimuli. Springer, Berlin, pp 161–175Google Scholar
  55. Steinpreis RE (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74:45–55PubMedGoogle Scholar
  56. Swanson CJ, Schoepp DD (2002) The group II metabotropic glutamate receptor agonist (−)-2-oxa-4-aminobicyclo(3.1.0)hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. J Pharmacol Exp Ther 303:919–927CrossRefPubMedGoogle Scholar
  57. Swerdlow NR, Bakshi V, Geyer MA (1996) Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279:1290–1299PubMedGoogle Scholar
  58. Tricklebank MD, Singh L, Oles RJ, Wong EHF, Iversen SD (1987) A role for N-methyl-d-aspartic acid in the discriminative stimulus properties of phencyclidine. Eur J Pharmacol 141:497–501CrossRefPubMedGoogle Scholar
  59. Vollenweider FX (1998) Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 31:92–103PubMedGoogle Scholar
  60. Winter JC (1974) Hallucinogens as discriminative stimuli. Fed Proc 33:1825–1832PubMedGoogle Scholar
  61. Winter JC (1978) Drug-induced stimulus control. In: Blackman DE, Sanger DJ (eds) Contemporary research in behavioral pharmacology. Plenum Press, New York, pp 209–237Google Scholar
  62. Winter JC, Fiorella DJ, Timineri DM, Filipink RA, Helsley SE, Rabin RA (1999) Serotonergic receptor subtypes and hallucinogen-induced stimulus control. Pharmacol Biochem Behav 64:283–293CrossRefPubMedGoogle Scholar
  63. Winter JC, Doat M, Rabin RA (2000) Potentiation of DOM-induced stimulus control by non-competitive NMDA antagonists: a link between the glutamatergic and serotonergic hypotheses of schizophrenia. Life Sci 68:337–344CrossRefPubMedGoogle Scholar
  64. Yamada S, Harano M, Annoh N, Nakamura K (1999) Involvement of serotonin 2A receptors in phencyclidine-induced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 46:832–838PubMedGoogle Scholar
  65. Zukin SR, Zukin RS (1979) Specific (3H)phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 76:5372–5376PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Department of Pharmacology and Toxicology, School of Medicine and Biomedical SciencesSUNY-BuffaloBuffaloUSA

Personalised recommendations